{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:25:24Z","timestamp":1792027524259,"version":"4.4.0"},"reference-count":9,"publisher":"Springer Science and Business Media LLC","issue":"S1","license":[{"start":{"date-parts":[[2020,6,1]],"date-time":"2020-06-01T00:00:00Z","timestamp":1590969600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T00:00:00Z","timestamp":1593043200000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs - Real World Outcomes"],"published-print":{"date-parts":[[2020,6]]},"DOI":"10.1007\/s40801-020-00195-7","type":"journal-article","created":{"date-parts":[[2020,6,25]],"date-time":"2020-06-25T12:02:21Z","timestamp":1593086541000},"page":"41-45","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin: A Two-Year, Multicenter, Retrospective Study"],"prefix":"10.1007","volume":"7","author":[{"given":"Nicholas W.","family":"Van Hise","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishnu","family":"Chundi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal","family":"Didwania","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Anderson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McKinsey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Roig","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akhilesh","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Russell M.","family":"Petrak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,6,25]]},"reference":[{"issue":"5","key":"195_CR1","doi-asserted-by":"publisher","first-page":"ofz181","DOI":"10.1093\/ofid\/ofz181","volume":"6","author":"NW Cortes-Penfield","year":"2019","unstructured":"Cortes-Penfield NW, Kulkarni PA. The history of antibiotic treatment of osteomyelitis. Open Forum Infect Dis. 2019;6(5):ofz181.","journal-title":"Open Forum Infect Dis."},{"issue":"4","key":"195_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.diagmicrobio.2018.03.008","volume":"91","author":"Q Yan","year":"2018","unstructured":"Yan Q, Karau MJ, Patel R. In vitro activity of oritavancin against planktonic and biofilm states of vancomycin-susceptible and vancomycin-resistant enterococci. Diagn Microbiol Infect Dis. 2018;91(4):348\u201350.","journal-title":"Diagn Microbiol Infect Dis"},{"issue":"1","key":"195_CR3","doi-asserted-by":"publisher","first-page":"e01873-17","DOI":"10.1128\/AAC.01873-17","volume":"62","author":"A Belley","year":"2018","unstructured":"Belley A, Arhin FF, Moeck G. Evaluation of oritavancin dosing strategies against vancomycin-resistant Enterococcus faecium isolates with or without reduced susceptibility to daptomycin in an in vitro pharmacokinetic\/pharmacodynamic model. Antimicrob Agents Chemother. 2018;62(1):e01873-17.","journal-title":"Antimicrob Agents Chemother."},{"issue":"6","key":"195_CR4","doi-asserted-by":"publisher","first-page":"ofy051","DOI":"10.1093\/ofid\/ofy051","volume":"5","author":"M Redell","year":"2018","unstructured":"Redell M, Moeck G, Lucasti C, Durso S, Kennedy C, Fusaro K, et al. A real-world patient registry for oritavancin demonstrates efficacy and safety consistent with the phase 3 SOLO program. Open Forum Infect Dis. 2018;5(6):ofy051.","journal-title":"Open Forum Infect Dis."},{"issue":"1","key":"195_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/phar.2057","volume":"38","author":"LT Schulz","year":"2018","unstructured":"Schulz LT, Dworkin E, Dela-Pena J, Rose WE. Multiple-dose oritavancin evaluation in a retrospective cohort of patients with complicated infections. Pharmacotherapy. 2018;38(1):152\u20139.","journal-title":"Pharmacotherapy"},{"issue":"4","key":"195_CR6","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1016\/j.ijantimicag.2018.11.023","volume":"53","author":"DB Chastain","year":"2019","unstructured":"Chastain DB, Davis A. Treatment of chronic osteomyelitis with multidose oritavancin: a case series and literature review. Int J Antimicrob Agents. 2019;53(4):429\u201334.","journal-title":"Int J Antimicrob Agents"},{"issue":"8","key":"195_CR7","doi-asserted-by":"publisher","first-page":"e90","DOI":"10.1002\/phar.1957","volume":"37","author":"DJ Delaportas","year":"2017","unstructured":"Delaportas DJ, Estrada SJ, Darmelio M. Successful treatment of methicillin susceptible Staphylococcus aureus osteomyelitis with oritavancin. Pharmacotherapy. 2017;37(8):e90\u2013e9292.","journal-title":"Pharmacotherapy"},{"issue":"2","key":"195_CR8","doi-asserted-by":"publisher","first-page":"77","DOI":"10.2174\/1871526517666161108130148","volume":"17","author":"SJ Antony","year":"2017","unstructured":"Antony SJ, Cooper LG. Use of oritavancin (novel new lipoglycopeptide) in the treatment of prosthetic joint infections (PJI): a possible alternative novel approach to a difficult problem. Infect Disord Drug Targets. 2017;17(2):77\u201380.","journal-title":"Infect Disord Drug Targets"},{"issue":"2","key":"195_CR9","first-page":"1","volume":"26","author":"R Foster","year":"2017","unstructured":"Foster R, Philavong K, Weissman S, Tang X, Bookstaver B. Oritavancin for treatment of daptomycin nonsusceptible vancomycin-resistant enterococci osteomyelitis. Infect Dis Clin Pract. 2017;26(2):1.","journal-title":"Infect Dis Clin Pract"}],"container-title":["Drugs - Real World Outcomes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40801-020-00195-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40801-020-00195-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T23:13:01Z","timestamp":1624576381000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40801-020-00195-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6]]},"references-count":9,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2020,6]]}},"alternative-id":["195"],"URL":"https:\/\/doi.org\/10.1007\/s40801-020-00195-7","relation":{},"ISSN":["2199-1154","2198-9788"],"issn-type":[{"value":"2199-1154","type":"print"},{"value":"2198-9788","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6]]},"assertion":[{"value":"25 June 2020","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used to assist in the preparation of this article. This article is part of a supplement wholly funded by Melinta Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"NVH has received speaker fees for Vabomere, which is owned by Melinta Therapeutics. VC, VD, MA, DM, IR, AS, and RP have no disclosures.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This retrospective study was approved for analysis and publication by the Western Institutional Review Board and has been performed in accordance with the ethical standards of the Declaration of Helsinki. Informed consent was waived as this study was retrospective.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}}]}}